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ologics. With immunosuppression of this kind, opportunistic 
infection becomes a key safety concern in patients with IBD.1 
In particular, the course of viral hepatitis is determined by the 
interaction between the virus and the host’s immunity. If im-
munity is compromised by immunosuppression, the risk of 
reactivation increases, and HBV reactivations in immunosup-
pressed patients have been associated with hepatic decom-
pensation in a considerable proportion of cases.2,3 Thus, risk 
assessment for viral hepatitis is one of the important quality 
process indicators for the management of IBD patients.4
In addition, several areas of Asia, including Korea, show in-
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REVIEW
INTRODUCTION
The treatment of IBD has been revolutionized over the past 
decade with the increasing use of immunomodulators and bi-
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termediate endemicity for the HAV, while HBV shows moder-
ate prevalence compared with United States and Western Eu-
rope. Thus, members of the IBD research group of the Korean 
Association for the Study of Intestinal Diseases (KASID) pro-




The IBD Research Group of the KASID decided to produce a 
evidence-based guideline on the prevention and manage-
ment of viral hepatitis in patients with IBD in April 2018. To 
establish the guidelines, a committee consisting of 10 gastro-
enterologists who were members of the KASID, 2 hepatolo-
gists and 1 professor of preventive medicine who acted as a 
methodologist was formed to develop the guidelines. The 
committee held 10 meetings, with all members in attendance, 
until the guidelines were completed, with the first meeting 
taking place on April 2, 2018. The guidelines addressed pre-
vention and management of viral hepatitis in patients with 
IBD. We focused on prevention and monitoring, and treat-
ment of viral hepatitis are not included in this guideline. The 
guidelines were generally made by adapting foreign and Kore-
an guidelines on the prevention and management of viral 
hepatitis in IBD. However, in the case of 3 key questions, no 
precise recommendations were included in the guidelines, 
thus new statements were produced by consensus of the pro-
fessional group.
2. Process of Development
1) Selection of the Key Questions
The key questions were selected among those raised in actual 
IBD clinic by the committee members. Three of the key ques-
tions were accessed by de novo consensus, with the remaining 
6 questions being answered by adaptation of previous guide-
lines.
2) Searching for Source Guidelines
We selected 183 articles that were published between January 
1966 and May 2018 by searching the MEDLINE/PubMed and 
National Guidelines Clearinghouse web sites.
3) Assessment of Guideline Quality and Final Selection
We identified 13 guidelines that were evidence-based, peer 
reviewed, and either national or international. According to 
the Appraisal of Guidelines Research and Evaluation II, each 
guideline was reviewed by 2 committee members for acade-
mic integrity and applicability to actual clinical practice. Dur-
ing the development of the current guideline, the 2015 Korean 
Association for the Study of the Liver (KASL) hepatitis B guide-
lines were updated as the 2018 KASL hepatitis B guidelines, 
and we adapted the updated guideline. Finally, all the 13 high-
ly qualified guidelines (Table 1)2,5-16 were selected, analyzed, 
and summarized in terms of their evidence and medical rec-
ommendations relevant to our guideline.
4) Adaptation
The evidence and recommendations of the 13 selected guide-
lines were reviewed, analyzed, and summarized to inform our 
recommendations and backgrounds. Some of the information 
therein was deemed to be insufficiently supported by evi-
dence, thus it was discussed in the IBD specialist meetings to 
be included in the guideline. The quality of the evidence and 
classification of the recommendations in these guideline are 
presented by the Grading of Recommendation Assessment, 
Development, and Evaluation format, by which we assessed 
the quality of evidence for each recommendation as high, 
moderate, low, and very low. The strength of each recommen-
dation was classified as strong or weak according to 4 main 
components: desirable and undesirable effects, quality of evi-
dence, values and preference, and resource allocation. The 
definition of quality of evidence and classification of the rec-
ommendations are shown in Table 2.
5) Delphi Process for Agreement to Recommendations
On June 14, 2019, the draft of the evidence-based guideline on 
the prevention and management of viral hepatitis in IBD was 
presented and proceeded with primary online voting by 40 
national IBD specialists who are members of the KASID. The 
voting participants evaluated each recommendation in the 
guidelines, stating either strongly agree, agree, uncertain, dis-
agree, or strongly disagree, and the recommendation was ad-
opted when more than 75% of the participants answered 
strongly agree or agree. The final result was written as a per-
centage and further classified into levels of agreement.
6) Review, Endorsement, and Distribution of Guidelines
The draft was reviewed and approved by the KASL. The final 
draft will be published by Intestinal Research and will be pro-
vided by the Korean Medical Guideline Information Center 
(http://www.guideline.or.kr). An updated version is awaiting 
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Table 1. Thirteen Guidelines Selected for Adaptation
Author Title Country Journal Year Volume/page
Farraye et al.5 ACG clinical guideline: preventive care in inflammatory 
bowel disease
USA American Journal of 
Gastroenterology
2017 112/241-258
Rahier et al.2 Second European evidence-based consensus on 
the prevention, diagnosis and management of 
opportunistic infections in inflammatory bowel 
disease
Europe Journal of Crohn's 
and Colitis
2014 8/443-468
European Association for the 
Study of the Liver6
EASL 2017 clinical practice guidelines on the 
management of hepatitis B virus infection
Europe Journal of 
Hepatology
2017 67/370-398
European Association for the 
Study of the Liver7
EASL recommendations on treatment of hepatitis C 
2018
Europe Journal of 
Hepatology
2018 69/461-511
Terrault et al.8 Update on prevention, diagnosis, and treatment of 
chronic hepatitis B: AASLD 2018 hepatitis B guidance
USA Hepatology 2018 67/1560-1599
Korean Association for the 
Study of the Liver (KASL)9
2017 KASL clinical practice guidelines management of 
hepatitis C: treatment of chronic hepatitis C
Korea Clin Mol Hepatol 2018 24/169-229
Korean Association for the 
Study of the Liver (KASL)10
KASL clinical practice guidelines for management of 
chronic hepatitis B
Korea Clin Mol Hepatol 2019 25/93-159
Singh et al.11 2015 American College of Rheumatology guideline for 
the treatment of rheumatoid arthritis
USA Arthritis Care & 
Research
2016 68/1-25
Rubin et al.12 2013 IDSA clinical practice guideline for vaccination of 
the immunocompromised host
USA Clinical Infectious 
Diseases
2014 58/309-318
Bombardier et al.13 Canadian Rheumatology Association recommendations 
for the pharmacological management of rheumatoid 
arthritis with traditional and biologic disease-
modifying antirheumatic drugs: part II safety
Canada The Journal of 
Rheumatology
2012 39/1583-1602
van Assen et al.14 EULAR recommendations for vaccination in adult 
patients with autoimmune inflammatory rheumatic 
diseases
Europe Annals of the 
Rheumatic Disease
2011 70/414-422
Bühler et al.15 Vaccination recommendations for adult patients with 
autoimmune inflammatory rheumatic diseases
Swiss Swiss Medical Weekly 2015 145/W14159
Cordeiro et al.16 Recommendations for vaccination in adult patients 
with systemic inflammatory rheumatic diseases from 
the Portuguese Society of Rheumatology
Portugal Acta Reumatológica 
Portuguesa
2016 41/112-130
ACG, American College of Gastroenterology; EASL, European Association for the Study of the Liver; AASLD, American Association for the Study of Liver 
Disease; KASL, Korean Association for the Study of the Liver; IDSA, Infectious Disease Society of America; EULAR, European League Against Rheumatism. 
Table 2. Definitions or Implications of the Levels of Evidence and Recommendations
Quality of evidence
   High We are very confident that the true effect lies close to that of the estimate of the effect.
   Moderate We are moderately confident about the effect estimate: the true effect is most likely to be close to the 
estimate of the effect, but there is a possibility that it is substantially different.
   Low Our confidence in the effect estimate is limited: the true effect may be substantially different from the 
estimate of the effect.
   Very low We have very little confidence in the effect estimate: the true effect is most likely to be substantially 
different from the estimate of the effect.
Classification of recommendations
   Strong Most patients should receive the recommended course of action.
   Weak Clinicians should recognize that different choices would be appropriate for different patients and that they 
must help patients to arrive at a management decision consistent with their values and preferences.
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publication and includes comments by users and newly pre-
sented evidence on the prevention and management of viral 
hepatitis in patients with IBD.
HEPATITIS A VIRUS
1. Epidemiology
The HAV is a small, non-enveloped, single-stranded RNA virus 
that is transmitted by the fecal-oral route. As such, transmis-
sion is increased by poor hygiene, and contaminated food or 
drink.17,18 HAV infection is usually a self-limiting illness that 
does not become chronic, unlike HBV or HCV. Instead, infec-
tion confers lifelong immunity and is preventable via vaccina-
tion. Furthermore, HAV rarely develops into acute fulminant 
hepatitis, which can cause death. 
HAV infection is prevalent around the world, but it shows 
various epidemiological patterns that depend on socioeco-
nomic conditions.19,20 Thus, to adopt appropriate vaccination 
policies, epidemiologists must ascertain the age-specific anti-
HAV seroprevalence rates in each country. In highly endemic 
areas, such as parts of Africa and Asia, the vaccine is not wide-
ly used as most adults acquire natural immunity. In areas of 
intermediate endemicity (such as Central and South Ameri-
ca, Eastern Europe, and parts of Asia), childhood transmis-
sion is less frequent, while adolescents and adults are more 
frequently infected, and outbreaks are common. These coun-
tries with intermediate endemicity would benefit most from 
universal immunization of children. In areas of low endemici-
ty (such as the United States and Western Europe), infection 
is less frequent, but the disease does occur among people in 
high-risk groups and as communitywide outbreaks. These 




Patients with IBD should be tested for HAV (IgG anti-HAV 
antibody) when they have no history of HAV vaccination or 
HAV hepatitis, or when the history of HAV vaccination is 
uncertain. In patients with IBD who are negative for the IgG 
anti-HAV antibody, vaccination should be administered 
(strong recommendation, very low level of evidence).
·  Level of agreement: strongly agree 50%, agree 50%, un-
certain 0%, disagree 0%, strongly disagree 0%
Most cases of hepatitis A are directly transmitted through the 
fecal-oral route, but other propagation paths include indirect 
transmission through feces-contaminated food or water, 
blood, or sexual activity. Thus, the Korea Centers for Disease 
Control and Prevention and the Advisory Committee on Im-
munization Practices of the United States Centers for Disease 
Control and Prevention, recommend protection (ideally vac-
cination) prior to potential hepatitis A exposure in the follow-
ing high-risk groups:21,22 those traveling to or working in coun-
tries with high or intermediate endemicity of HAV, men who 
engage in sexual activity with men, users of all illicit drugs, 
those working with HAV-infected primates or with HAV in a 
research laboratory, those with chronic liver disease, those 
with clotting factor disorders, and those in direct contact with 
others who have hepatitis A.
Patients with IBD are not included in this high-risk group, 
and their potential for hepatitis A exposure might not different 
from those without IBD. However, they are often treated with 
immunomodulators and biologics for long periods, as single 
agents or in combination, and pre-exposure protection (vacci-
nation) is recommended in immunocompromised patients, 
as well as in those with chronic liver disease.21
In HAV, IgG antibodies appear early in the infection phase 
and remain throughout the patient’s life, preventing disease. 
The decision to pursue prevaccination serological testing in 
adults should be based on the expected prevalence of immu-
nity within the given population, as well as on the cost of vac-
cination compared with the cost of testing. According to rapid 
economic development in Korea, a rapid epidemiological shift 
in HAV infection has occurred.20,23 Most adults had immunity 
to HAV because of childhood exposure in 1980, but people in 
their teens or twenties had less than 10% of anti-HAV IgG in 
2010.23 Thus, the number of adult infected with acute hepatitis 
A has increased rapidly over the past decade. Since May 2015, 
HAV vaccination has been recommended for all children be-
tween 12 and 23 months in Korea, with high-risk groups being 
prioritized. Considering the age differences in anti-HAV sero-
prevalence, the cost of testing, and vaccine prices, those under 
30 years of age, who have low HAV antibody rates, are recom-
mended to receive the vaccine without prevaccination sero-
logical testing, while those over 40 years of age should under-
go a prevaccination serological test and receive the vaccine if 
the antibody is absent.22
In patients with IBD, we recommend HAV testing (IgG anti-
HAV antibody) in patients with no history of HAV vaccination 
or HAV-related hepatitis, as well as in those whose history of 
HAV vaccination is uncertain. In patients with IBD who are 
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HAV vaccination should be administered to patients with 
IBD using inactivated vaccine, and again at least 6 months 
later (strong recommendation, with very low level of evi-
dence).
·  Level of agreement: strongly agree 35%, agree 55%, un-
certain 7.5%, disagree 0%, strongly disagree 2.5%
Hepatitis A is preventable by vaccination. Currently, inactivat-
ed HAV vaccines are used as standard vaccination agents and 
are licensed for administration in a 2-dose schedule given at 
6- to 12-month intervals (single dose plus booster dose). Since 
1992, 4 interchangeable inactivated monovalent hepatitis A 
vaccines have become, available which provided protection 
against all strains of the virus.24 Protective levels of anti-HAV 
viruses, persists for at least 20–25 years after vaccination.25 Al-
though a live, attenuated hepatitis A vaccine is used in some 
areas because it is cheaper, it has a major disadvantage in that 
reverse mutation of the live vaccine strains is theoretically 
possible.26 Moreover, live vaccines do not offer post-exposure 
protection because they only illicit a slow immune response.26
The immune and memory response to the booster dose 
and the post-booster geometric mean titer, are independent of 
the interval since initial vaccination.27 In one study, the effect 
of the booster on seroprotection was the same across all sexes 
and age-groups, and the longest time interval between initial 
dose and booster dose was 11 years, indicating that booster 
dose can be highly immunogenic for up to 11 years after pri-
mary vaccination.27
Hepatitis A vaccines are safe and highly immunogenic in 
healthy adults. After 2 vaccinations, with an interval of ≥ 6 
months, protective antibody titers reported in > 99% of pa-
tients.28-30 Regarding antibody response according to the num-
ber of hepatitis A vaccinations, several studies involving pa-
tients with various diseases and medications have reported a 
significantly higher response after 2 vaccinations than after 
one vaccination.27,31-33
Immunosuppressive therapy can lower the antibody response 
rate of a vaccination. One study including 419 patients with 
IBD investigated the immunogenicity of the HAV vaccine.34 
Patients were given the HAV vaccine at 0 and 6–12 months, 
and IgG anti-HAV antibody was measured 1 to 3 months after 
the second dose.34 The overall seroconversion rate was 97.6%, 
but it was significantly lower in patients treated with the anti-
TNF monoclonal antibody than in those not treated (92.4% vs. 
99.1%, respectively; P = 0.001). Furthermore, the seroconver-
sion rate was significantly lower in patients treated with ≥ 2 
than with, < 2 immunosuppresants (92.6% vs. 98.4%, P = 0.03). 
No significant differences in seroconversion rates were seen 
between patients treated with anti-TNF alone and those treat-
ed with anti-TNF plus other immunomodulators (OR, 1.2; 95% 
CI, 0.2–5.6).34 Therefore, the optimal timing to vaccinate pa-
tients with IBD against HAV may be at IBD diagnosis, and the 
vaccine is recommended to be administered prior to immuno-
suppressive therapy. If HAV vaccines were not available prior 
to immunosuppressive therapy, it also is recommended to be 
administered to patients with treated immunosuppression.12 
As the main transmission route of HAV is the fecal-oral 
route, HAV transmitted through ingestion of contaminated 
food or drink and causes acute hepatitis.35 Soon after IBD di-
agnosis, clinicians should check hepatitis A vaccination histo-
ry for patients, evaluate their protective antibody status, and 
carry out vaccination, and again in patients who are planning 
travel to areas that are highly endemic for HAV, including 
Southeast Asia, Eastern Europe, and Africa.35 Patients should 
also be educated in hand sanitation and cautioned about con-
taminated food and water.
In general, routine anti-HAV IgG testing is not necessary after 
vaccination, since the seroconversion rate is very high after the 
standard 2-dose vaccinations. However, as described above, 
antibody production after vaccines may be reduced in patients 
undergoing immunosuppressive therapies, thus measurement 
of anti-HAV IgG in such patients could be considered 4–6 
weeks after a primary course of vaccinations.15 There are no 
data on the efficacy and safety of revaccination in patients who 




The HBV is an infectious disease, with 248 million carriers 
globally. About 600,000 people die of HBV-related liver dis-
ease annually.36 Although effective vaccination programs are 
underway, and the rate of new HBV infections has been signif-
icantly reduced, HBV is still a major cause of morbidity and 
mortality.
HBV can be clinically classified as acute and chronic. In the 
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acute phase, the virus may manifest as subacute, non-icteric 
hepatitis, icteric hepatitis, and sometimes fulminant hepatitis. 
The chronic phase can be an asymptomatic carrier phase, but 
it may also manifest as chronic hepatitis, liver cirrhosis, or he-
patocellular carcinoma. Both acute and chronic HBV infection 
may be accompanied by extrahepatic symptoms.
The prevalence of the virus varies by country and region, 
from 2% in countries with low prevalence (e.g., UK, Canada, 
Western Europe, etc.), 2%–7% in those with moderate preva-
lence (e.g., South Korea, Mediterranean countries, Japan, Cen-
tral Asia, Middle East, and parts of South America), and more 
than 8% in West Africa and South Sudan, which have the high-
est prevalence rates.37,38
In Korea, HBV vaccination of all newborns has been imple-
mented since 1983 (vaccination coverage rate: 79.7%), and the 
Expanded Program on Immunization (coverage rate: 98.9%) 
was rolled out in 1995. As a result, Korea is no longer an en-
demic area, but is classified as having intermediate endemici-
ty.39,40 In the 1980s, HBsAg-positive carriers comprised 8%–
10% of the population. The equivalent rates were 4.6% in the 
1990s and 2.9% in 2010. At younger ages, the positive rate of 
HBsAg was 2.2% in 1998, 1.9% in 2001, and 0.3% in 2016. In 
IBD patients, the prevalence of chronic HBV infection (posi-
tive HBsAg, positive anti-HBc, and negative anti-HBs) was 
3.8% and past infection (negative HBsAg, positive anti-HBc, 
and positive or negative anti-HBs) was 26.2%.41 The World 
Health Organization (WHO) has estimated that the preva-
lence of chronic hepatitis B infection in children under 5 years 
will be 1% in 2020 and 0.1% in 2030.
2. Screening
Statement 3
All patients with IBD should be tested for HBV (HBsAg, an-
ti-HBs, anti-HBc IgG) at the time of IBD diagnosis. HBV 
DNA should be quantified in patients with positive HBsAg 
or anti-HBc IgG (strong recommendation, with high level 
of evidence).
·  Level of agreement: strongly agree 95%, agree 5%, un-
certain 0%, disagree 0%, strongly disagree 0%
To the patients in countries with moderate to high prevalence, 
test for HBV before starting immunosuppressive therapy is 
recommended.42-44 Moreover, reactivation of HBV infection, 
with serious consequences, has been reported in immuno-
suppressed patients with IBD.45 Therefore, all patients with 
IBD should be assessed for HBV infection (HBsAg, anti-HBs, 
anti-HBc) or immunization status. Patients who are positive 
for HBsAg, HBeAg, anti-HBe, and HBV DNA should also be 
evaluated,2 as should HBV infection. Vaccination of the unim-
munized patients is recommended, especially before biologic 
treatments are started.2,12 The risk of HBV reactivation can be 
increased in patients who are receiving immunosuppressive 
therapy (including biologics) and are (1) HBsAg-positive or 
(2) HBsAg-negative plus anti-HBc positive.42 In one study, the 
rate of HBV reactivation during biologic treatments for pa-
tients with a rheumatic disease was 12.3% in HBsAg-positive 
plus anti-HBc positive patients,46 while in another it was 1.7% 
in HBsAg-positive plus anti-HBc positive and HBsAg-negative 
plus anti-HBc positive patients.47 Therefore, both HBsAg and 
anti-HBc (IgG or total) should be tested. HBV DNA should be 
quantified in patients scheduled to start immunosuppressive 
therapy who are either HBsAg-positive or anti-HBc-positive at 
diagnosis.3
The role of anti-HBs screening before immunosuppressive 
therapy remains unclear, and the presence of anti-HBs does 
not imply prevention of HBV reactivation. However, anti-HBs 
testing may be helpful for detecting past infection in patients 
who are HBsAg-negative and anti-HBc-positive. Furthermore, 




HBV vaccination should be administered to IBD patients 
who have negative serology for HBV (HBsAg, anti-HBc IgG, 
and anti-HBs negative) with no or unclear HBV vaccination 
history at the time of IBD diagnosis (strong recommenda-
tion, high level of evidence).
·  Level of agreement: strongly agree 72.5%, agree 20%, 
uncertain 5%, disagree 0%, strongly disagree 2.5%
The prevalence of HBV in patients with IBD is not different 
from that in the general population.51-53 In all HBV seronega-
tive patients (HBsAg, anti-HBc, and anti-HBs negative) with 
IBD, regardless of the degree of immunosuppression, HBV 
vaccination is recommended.2,5 However, some questions 
have been raised about whether universal vaccination is nec-
essary in areas with low HBV prevalence.54,55 The WHO rec-
ommended administering the HBV vaccine after birth—in all 
countries with high, intermediate and low endemicity.56 De-
spite these recommendations, the rate of routine HBV vacci-
nation in patients with IBD is not high,53,57 according to a study 
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conducted in Spain involving more than 2,000 patients with 
IBD, only 12% of patients were administered HBV vaccine.53 
Since HBV infection is relatively common in Korea, specific 
attention should be given to HBV serology testing and HBV 
vaccination in patients with IBD.
It is not yet clear whether patients with isolated anti‐HBc 
positivity (seronegative for both HBsAg and anti‐HBs and se-
ropositive for anti-HBc IgG) require vaccination against HBV. 
The most common cause of isolated anti-HBc positive cases 
in areas with high prevalence of hepatitis B, such as Korea, is 
past HBV infection, where immunization is not necessary, but 
could be considered in an environment where the risk of ex-
posure to HBV is high.58,59
HBV vaccines should be administered before starting immu-
nosuppression if feasible, and the inactive vaccine is recom-
mended at least 2 weeks before. As the immune response to 
vaccination is generally decreased by immunosuppression, 
patients with IBD should be administered HBV vaccine soon 
after diagnosis, immunosuppressive therapy is commenced, 
where possible, especially because the disease follows an un-
predictable course and necessitates immunosuppressive ther-
apy.5,12 According to a meta-analysis based on a random-ef-
fects model, the pooled rate of a response to HBV vaccination 
among patients with IBD was 61% (95% CI, 53%–69%) and no 
immunosuppressive therapy was predictive of an immune re-
sponse compared to immunomodulatory (RR, 1.33; 95% CI, 
1.08–1.63) or anti-TNF-α (RR, 1.57; 95% CI, 1.19–2.08) thera-
py.60 However, in patients who require immunosuppression 
from the time of diagnosis of IBD, HBV vaccination could be 
administered with commencement of immunosuppressive 
drugs.
The standard course of hepatitis B vaccination consists of 3 
doses administered at 0, 1, and 6 months, and antibodies are 
usually produced in more than 90% of general population who 
vaccinated.61 This standard vaccination may be ineffective in 
eliciting seroprotection in the majority of previously unvacci-
nated patients with IBD, particularly those being treated using 
immunosuppressive therapy.62-64 Higher or reinforced doses 
may be needed to achieve anti-HBs response in immunocom-
promised patients.42,65 In previous study involving 148 patients, 
41% of those receiving standard cycle of the commercial hepa-
titis B vaccine at 0, 1, and 6 months attained anti-HBs titers 
> 10 IU/L, compared with 75% of patients receiving an accel-
erated double-dose protocol at 0, 1, and 2 months.64 A study 
reported that the receiving accelerated double-dose at 0, 1, 2 
months followed by revaccination (0, 1, and 2 months) at a 
double-dose if no adequate response is achieved has demon-
strated a higher efficacy than the standard schedule.66
Statement 5
Patients with IBD require to undergo serology testing 1 to 3 
months after administration of the last dose of vaccination 
to assess whether they require revaccination (weak recom-
mendation, with very low level of evidence).
·  Level of agreement: strongly agree 20%, agree 55%, un-
certain 20%, disagree 5%, strongly disagree 0%
Generally, immune response to vaccination in patients on 
immunomodulator monotherapy are not different from con-
trols.66 Therefore, IBD itself may  play a role in the suboptimal 
response to the HBV vaccine.67 In patients receiving mono-
therapy with anti-TNF, some but not all studies have demon-
strated a decreased immune response compared with con-
trols or patients on 5-ASAs. The immunogenicity of inactivated 
vaccines may be preserved when administered on the same 
day as infusion of the anti-TNF, but it may be reduced when 
the full immunosuppressive effect of the inhibitor has devel-
oped after several weeks. This was observed in patients with 
rheumatoid arthritis, but patients with ankylosing spondylitis 
revealed good antibody responses, regardless of the time of 
infliximab infusion.68 In patients prescribed both an immuno-
modulator and anti-TNF agent, the immune response to vac-
cines is lower than in those on monotherapy with an immu-
nomodulator, anti-TNF, or 5-ASAs.69 In contrast, vedolizumab 
which shows gut-selective mechanism does not influence the 
response to parenterally administered HBV vaccine, but did 
reduce the response to oral cholera vaccine.70
In healthy individuals, routine immunity testing after vacci-
nation is not necessary. However, in the patients with IBD, 
whose treatment depends on immune status, serology testing 
1 to 3 months after administration of the last dose are required 
to assess the need for revaccination.44,56,71
Statement 6
An additional cycle of revaccination is recommended if se-
roprotection is not achieved after HBV vaccination in pa-
tients with IBD (weak recommendation, with low level of 
evidence).
·  Level of agreement: strongly agree 12.5%, agree 70%, 
uncertain 17.5%, disagree 0%, strongly disagree 0%
An additional cycle (0, 1, and 6 months) of revaccination is 
recommended if seroprotection is not achieved. There is some 
debate about what titer level represents adequate protection 
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against hepatitis B, with some groups recommending titers of 
anti-HBs above 10 IU/L, and others recommending titers above 
100 IU/L.61,72 According to recently published clinical practice 
guidelines for hepatitis B in Korea, the level of protective titer 
of anti-HBs is defined as above 10 IU/L, and if the anti-HBs 
level is below 10 IU/L in immunosuppressed patients, addi-
tional vaccinations are recommended.3 In nonresponders to 
HBV vaccination, seroprotection was achieved in 44%–100% 
after 3 additional doses of revaccination. Considering the cost-
effectiveness in nonresponders to HBV vaccination, vaccina-
tion can be discontinued if anti-HBs ≥ 10 mIU/mL after one 
month of additional first dose (4th) of administration, howev-
er, additional second and third doses (5th and 6th) are admin-
istered if anti-HBs < 10 mIU/mL. Then HBV serology testing 
should be performed 1 to 2 months after completion of vacci-
nations.73
Although primary hepatitis B vaccination series is complet-
ed and HBV seroprotection is achieved, it is highly likely that 
patients with IBD, especially those on immunosuppressive 
therapy, experience loss of seroprotection (anti-HBs level be-
low 10 IU/L) during follow-up. In fact, seroprotection falls by 
18% per patient-year in this regard.74 Therefore, serum anti-
HBs titers should be monitored in patients with IBD who are 
receiving immunosuppressive therapy, even if HBV seropro-
tection is achieved after complete vaccination. Based on ex-
pert opinion, anti-HBs should be monitored every 12–24 
months, especially in the intermediate- and high-prevalence 
countries.2,5
Immunocompromised patients with IBD who have loss of 
seroprotection during follow-up should be advisable given a 
single booster dose, and clinicians should consider adminis-
tering another vaccination series at the regular dose if anti-
HBs titers fail to rise sufficiently. A booster dose is an extra ad-
ministration of a vaccine after an earlier (prime) vaccination, 
which differ from revaccination that requires an entire addi-
tional cycle (0, 1, and 6 months) of vaccination. T and B cell 
immune response to the vaccine booster dose is better pre-
served than that to primary vaccination, because more mem-
ory T and B cells are present, having been induced by the pre-
vious dose.75,76 In one prospective study, a booster dose re-
stored immune response in 76% of pediatric patients with IBD 
who had lost seroprotection.77 In cases of HIV-infected chil-
dren, approximately 30% of patients on antiviral therapy who 
were vaccinated had no protective titers 3 years after HBV 
vaccination, but 82% had an anamnestic response to a single 
booster dose.78 Thus, a booster dose in patients with IBD on 
immunosuppressive therapy usually generates protective ti-
ters, but antibody responses may be lower than in those with-
out immunosuppressive therapy.
A booster dose may be unnecessary in immunocompetent 
patients with IBD, even though protective titers of anti-HBs 
wane during follow-up. Long-term follow-up studies have 
demonstrated that immune memory persists in immunocom-
petent individuals, even though anti-HBs levels decline.79
4. Antiviral Prophylaxis
Statement 7
HBsAg-positive and/or HBV DNA-positive (i.e., those with 
chronic HBV infection) IBD patients who require moderate-
to-high risk immunosuppressive therapy should receive an-
tiviral prophylaxis that starts before and continue for at least 
6–12 months after the duration of immunosuppression 
(strong recommendation, with high level of evidence).
·  Level of agreement: strongly agree 87.5%, agree 12.5%, 
uncertain 0%, disagree 0%, strongly disagree 0%
HBV reactivation is defined as active inflammation occurring 
after inactivity in chronic hepatitis B or after resolution of a 
past HBV infection. HBV reactivation is classified as follows: 
(1) exacerbation of chronic HBV infection in patients who are 
HBsAg-positive, or (2) relapse of past HBV infection in pa-
tients who are HBsAg-negative plus anti-HBc-positive.80 Exac-
erbation of chronic HBV infection is defined as a more than a 
100-fold rise in serum HBV DNA compared to baseline among 
patients who are HBsAg-positive.3 Relapse of past HBV infec-
tion is detected based on reverse seroconversion (serorever-
sion) from HBsAg-negativity to HBsAg-positivity, or on the de-
tection of serum HBV DNA in patients who are HBsAg-nega-
tive plus anti-HBc-positive.3 In patients with HBV reactivation, 
a hepatitis flare-up can occur, which is evidenced demonstrat-
ed by a more than 3-fold or 100 IU/L increase in serum ALT 
compared to baseline.81,82
The risk of HBV reactivation depends on host factors, viro-
logical factors, and type and degree of immunosuppression.83 
The host factors include male sex, older age, cirrhosis, and co-
morbidity requiring immunosuppressive therapy, such as ma-
lignancy and IBD.84,85 Virological factors comprise high base-
line HBV DNA level, HBeAg positivity,86-88 and possibly HBV 
genotype.89-91 Clinicians should consider assessing host and 
virological risk factors to decide whether antiviral prophylaxis 
should be initiated before starting immunosuppressive thera-
py. Immunosuppression induces HBV reactivation in up to 
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50% of patients undergoing organ transplantations or antican-
cer chemotherapy if antiviral therapy is not administered.2 HBV 
reactivation has been also reported in patients with rheuma-
tological diseases or IBD who are receiving anti-TNF, such as 
infliximab, etanercept, or adalimumab.86,92-96 In two large, ret-
rospective cohort studies, liver dysfunction occurred in 25%–
36% of HBsAg-positive patients with IBD receiving immuno-
suppressive agents, including corticosteroids, immunomodu-
lators, and anti-TNF, and more than 50% of patients who expe-
rienced HBV reactivation had liver failure.45,97 Importantly, 
most cases of HBV reactivation developed in patients receiv-
ing 2 or more immunosuppressive agents for a long period 
who were positive for HBV DNA and/or had not undergone 
antiviral prophylaxis. In contrast, HBV reactivation seems to 
be extremely rare in HBsAg-negative and anti-HBc-positive 
patients with IBD.45,51
The risk of HBV reactivation can be divided into high risk 
( ≥ 10%), moderate risk (1%–10%), and low risk ( < 1%) based 
on the type of immunosuppressive therapy used, which was 
stratified by HBsAg-positive, or HBsAg-negative plus anti-HBc 
positive.83,98,99 Prophylactic therapy with potent oral antiviral 
agents to treat HBV is highly recommended in patients at high 
or moderate risk of reactivation. In contrast, close monitoring 
for HBV reactivation is recommended in patients at low risk of 
reactivation. The risk of HBV reactivation is listed in Table 3.
Long-term moderate-to-high dose corticosteroid therapy 
(oral prednisone ≥ 10 mg/day over 4 weeks) increases the risk 
of HBV reactivation in patients who are HBsAg-positive, or 
HBsAg-negative plus anti-HBc positive.98 Long-term, low-dose 
corticosteroid therapy (oral prednisone of less than 10 mg/
day over 4 weeks) may also increase the risk of reactivation up 
to 10% in patients who are HBsAg-positive,99 which necessi-
tates antiviral prophylaxis. In contrast, patients receiving short-
term oral prednisone over 1 week are at low risk of reactiva-
tion and do not need antiviral prophylaxis.98 Immunophilin 
inhibitors such as cyclosporine and tacrolimus may increase 
the likelihood of HBV reactivation.100 However, patients receiv-
ing methotrexate, azathioprine or 6-mercaptopurine do not 
require antiviral prophylaxis because they are at low risk of 
HBV reactivation.98
Anti-TNF treatments, such as infliximab and adalimumab, 
confer a high risk of HBV reactivation—up to 40% in patients 
who are HBsAg-positive.95,101 Furthermore, this risk is higher 
when using infliximab than when using etanercept, which is 
correlated with potency. TNF-α may regulate the adaptive im-
mune response to HBV infection, and recent evidence has 
demonstrated that TNF-α and related cytokines may play a 
crucial role in regulating covalently closed circular DNA and 
HBV replication.102 Thus, TNF-α blockade can lead to enhanced 
HBV replication and subsequent reactivation. Anti-integrins, 
Table 3. Risk of HBV Reactivation Related to Immunosuppressive Therapy for IBD 
Risk of reactivation Immunosuppressive agents Antiviral prophylaxis
HBsAg-positive 
   High risk (≥10%) Long-term moderate-to-high dose corticosteroids (prednisone ≥10 mg/day, ≥4 weeks)
More potent anti-TNF-α (infliximab, adalimumab, certolizumab, and golimumab) 
Yes
   Moderate risk (1%–10%) Long-term low-dose corticosteroids (prednisone <10 mg/day, ≥4 weeks)
Less potent anti-TNF-α (etanercept) 
Cytokine-based therapies (ustekinumab, natalizumab, and vedolizumab) 
Immunophilin inhibitors (tacrolimus, cyclosporine)
Yes




   High risk (≥10%) Not available Yes
   Moderate risk (1%–10%) Long-term moderate-to-high dose corticosteroids (prednisone ≥10 mg/day, ≥4 weeks)
Less potent anti-TNF-α (etanercept) 
Cytokine-based therapies (ustekinumab, natalizumab, and vedolizumab) 
Immunophilin inhibitors (tacrolimus, cyclosporine)
Noa
   Low risk (<1%) Short-term corticosteroids (≤1 week)
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such as natalizumab, vedolizumab, and ustekinumab, have 
been associated with a moderate risk of HBV reactivation in 
patients who are HBsAg-positive,103,104 perhaps because the 
liver is an immune organ with an active influx and efflux of im-
mune cells,105 so these agents may reduce local immune con-
trol of HBV replication in the liver.
In patients who are HBsAg-negative plus anti-HBc-positive, 
antiviral prophylaxis should be considered on a case-by-case 
basis, considering comorbidities, prevalence of anti-HBc posi-
tivity, and health care resources.5 However, antiviral prophy-
laxis is not generally recommended in patients receiving im-
munosuppressive therapy who are HBsAg-negative plus anti-
HBc-positive and are at low or moderate risk of HBV reactiva-
tion.3,6 The crucial virological event in patients who are anti-
HBc-positive is HBsAg reappearance (seroreversion), which is 
closely associated with hepatitis flare.106 Therefore, pre-emp-
tive therapy is based upon monitoring of HBsAg, HBV DNA, 
and ALT during and after immunosuppression in patients who 
are HBsAg-negative plus anti-HBc-positive, and antiviral pro-
phylaxis should be considered in cases of HBsAg seroreversion 
and/or detectable HBV DNA, regardless of serum ALT.3,6,8,83
Antiviral prophylaxis should be initiated in patients who are 
HBsAg-positive and/or have detectable HBV DNA before start-
ing immunosuppressive therapy—most literature specifies 7 
days before.107 Entecavir and tenofovir are preferred to other 
antiviral agents, because they have high potency and a high 
resistance barrier, and because several meta-analyses have as-
sociated them with reduced reactivation, hepatitis, and mor-
tality.98,107-109 The antiviral prophylaxis is recommended to be 
administered 6 to 12 months after discontinuation of immu-
nosuppression,107 as HBV reactivation beyond 12 months re-
ported, particularly in patients who received rituximab (anti-
CD20 antibody).110-112 
5. Monitoring 
In patients who are HBsAg-positive, anti-HBV prophylaxis is 
recommended independent of serum HBV DNA, and HBV 
DNA and ALT should be monitored every 3 to 6 months dur-
ing, and for at least 12 months after anti-HBV prophylaxis, be-
cause many HBV reactivations develop after antiviral therapy 
has been discontinued.113-117
Patients who are HBsAg-negative plus anti-HBc-positive are 
at lower risk of HBV reactivation than those who are HBsAg-
positive. However, HBV reactivation can also occur in these 
patients,118 and HBsAg seroreversion is constantly associated 
with hepatitis flare-ups, even though HBV DNA detection 
leads to seroreversion and hepatitis in only 50% of cases.106 
These patients should be monitored every 2 to 3 months for 
increased ALT, HBsAg and changes in HBV DNA, both during 
and after immunosuppressive therapy. Antiviral treatment 




The global HCV prevalence is estimated at 2.5% (177.5 million 
of HCV-infected adults), ranging from 2.9% in Africa and 1.3% 
in the Americas.119 In the early 1990s, the prevalence of HCV 
was reported as 1.7% by enzyme immunoassay method among 
Korean individuals who underwent health screening pro-
gram.120 More recently, a nationwide seroepidemiology study 
demonstrated that HCV antibody positivity rate in Korea was 
0.78%.121 Additionally, HCV antibody positivity rate tended to 
increase with age. The rate was 0.34%, 0.41%, 0.60%, 0.80%, 
1.53%, and 2.31% in individuals aged 20–29, 30–39, 40–49, 50–
59, 60–69, and ≥ 70 years, respectively.121 A high-risk group for 
HCV infection includes individuals who inject drugs, patients 
who undergo dialysis, those with hemophilia or Hansen’s dis-
ease, and children born to HCV-positive mothers.119,122 HCV is 
typically transmitted parenterally. Sexual, perinatal, and spo-
radic transmission are reported relatively infrequently.2
Statement 8
HBV status should be carefully monitored in patients with 
IBD who are positive for HBsAg or anti-HBc and treated 
using immunosuppressive therapy (strong recommenda-
tion, high evidence level). In patients who are positive for 
HBsAg, HBV DNA and ALT levels should be monitored ev-
ery 3 to 6 months during prophylaxis, and for at least 12 
months after cessation of anti-HBV prophylaxis (strong 
recommendation, low evidence level).
·  Level of agreement: strongly agree 47.5%, agree 52.5%, 
uncertain 0%, disagree 0% strongly disagree 0%
In patients who are HBsAg-negative and anti-HBc positive, 
HBsAg, HBV DNA, and ALT should be assessed every 2–3 
months. Antiviral therapy is recommended when HBV re-
activation occurs (strong recommendation, very low evi-
dence level).
·  Level of agreement: strongly agree 45%, agree 55%, un-
certain 0%, disagree 0%, strongly disagree 0%
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2. Screening
Statement 9
We recommend testing newly diagnosed patients with IBD 
for IgG anti-HCV antibody. If positive, HCV RNA titer 
should be checked to confirm HCV infection (strong for 
recommendation, moderate level of evidence).
·  Level of agreement: strongly agree 85%, agree 12.5%, 
uncertain 2.5%, disagree 0%, strongly disagree 0%
Thanks to recent advancements in medication for HCV, most 
infections can be cured. In fact, HCV elimination is now an 
achievable goal, and the WHO has set an ambitious but achiev-
able 2030 elimination target.123 Although patients with IBD are 
not a high-risk group for HCV infection, those who are infect-
ed with HCV should be treated in the same way as the general 
population. In addition, patients with IBD are at risk of wors-
ening liver function due to immunosuppressive therapy such 
as TNF-α inhibitors.124 Therefore, we recommend that patients 
with IBD be tested for IgG anti-HCV antibody at the time of 
IBD diagnosis. When IgG anti-HCV antibody is detected by 
screening,125 the patients’ HCV RNA titer should be tested to 
confirm HCV infection.126 If infection is confirmed, patients 
should be treated according to the HCV clinical practice guide-
lines.7 If possible, HCV infection should be treated before bio-
logic treatments of IBD are initiated. However, if HCV-infected 
patients with IBD cannot delay their immunosuppressive 
therapy, their liver function should be monitored closely. In a 
previous systematic review involving a total of 153 patients 
with HCV who had been treated using TNF-α inhibitor, mainly 
for rheumatoid arthritis, worsening HCV infection was identi-
fied in only one patient.124 The benefits of immunosuppressive 
therapy in patients with IBD who have active disease status 
likely outweigh the risks of the therapy. However, based on 
current existing evidence, we cannot recommend simultane-
ous treatment of IBD (using a TNF-α inhibitor) and HCV in-
fection. Drug-drug interactions between HCV and IBD medi-
cations may occur, which may increase drug toxicity or reduce 
drug efficacy.7
CONCLUSION
In patients with IBD, opportunistic infection is a key safety 
concern with the increasing use of immunomodulators and 
biologics. As HBV reactivation in immunosuppressed patients 
has been associated with hepatic decompensation in a con-
siderable proportion of cases, clinicians are faced with many 
challenges in the management of patients with IBD.
 As Korea is still an area of intermediate HAV and HBV en-
demicity, we hope that these guidelines for the prevention and 
management of viral hepatitis in IBD will prevent hepatitis vi-
ral infection and reactivation, and that it will lessen confusion 
among physicians and researchers. 
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